The outcome of intravenous and inhalation anesthesia after pancreatic cancer resection: a retrospective study.
Disease-free survival
INHA
Overall survival
Pancreatic cancer
SIPTW
TIVA
Journal
BMC anesthesiology
ISSN: 1471-2253
Titre abrégé: BMC Anesthesiol
Pays: England
ID NLM: 100968535
Informations de publication
Date de publication:
30 05 2022
30 05 2022
Historique:
received:
15
01
2022
accepted:
18
05
2022
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
3
6
2022
Statut:
epublish
Résumé
Different types of anesthesia may affect cancer patient's outcomes, we compared the overall survival (OS) and disease-free survival (DFS) of patients with pancreatic cancer under total intravenous and inhalation anesthesia. The authors collected the electronic medical records of patients who had accepted at a pancreatectomy from January 1, 2010 to December 31, 2016. Patients respectively received total intravenous anesthesia (TIVA) or inhalational anesthesia (INHA). Stabilized inverse probability of treatment weighting (SIPTW)was used to minimize differences. Kaplan-Meier survival was established to analyze the influence of sort of anesthesia on disease-free and overall survival. We compare the effects of each sort of anesthesia on cancer recurrence or metastasis and all-cause mortality. A total of 463 patients who had undergone pancreatic cancer resection were collected in this study, of which 421 patients were available (TIVA group, n = 114 INHA group, n = 307). After SIPTW there were no significant differences between the two groups in disease-free survival (hazard ratio, 1.01, 95%CI, 0.78 to 1.29, P = 0.959) or overall survival (hazard ratio, 1.11, 95%CI, 0.87 to 1.42, P = 0.405). In conclusion, the present study showed no significant difference in overall survival and disease-free survival between total intravenous anesthesia and volatile anesthesia.
Sections du résumé
BACKGROUND
Different types of anesthesia may affect cancer patient's outcomes, we compared the overall survival (OS) and disease-free survival (DFS) of patients with pancreatic cancer under total intravenous and inhalation anesthesia.
METHODS
The authors collected the electronic medical records of patients who had accepted at a pancreatectomy from January 1, 2010 to December 31, 2016. Patients respectively received total intravenous anesthesia (TIVA) or inhalational anesthesia (INHA). Stabilized inverse probability of treatment weighting (SIPTW)was used to minimize differences. Kaplan-Meier survival was established to analyze the influence of sort of anesthesia on disease-free and overall survival. We compare the effects of each sort of anesthesia on cancer recurrence or metastasis and all-cause mortality.
RESULTS
A total of 463 patients who had undergone pancreatic cancer resection were collected in this study, of which 421 patients were available (TIVA group, n = 114 INHA group, n = 307). After SIPTW there were no significant differences between the two groups in disease-free survival (hazard ratio, 1.01, 95%CI, 0.78 to 1.29, P = 0.959) or overall survival (hazard ratio, 1.11, 95%CI, 0.87 to 1.42, P = 0.405).
CONCLUSIONS
In conclusion, the present study showed no significant difference in overall survival and disease-free survival between total intravenous anesthesia and volatile anesthesia.
Identifiants
pubmed: 35637441
doi: 10.1186/s12871-022-01703-8
pii: 10.1186/s12871-022-01703-8
pmc: PMC9150331
doi:
Substances chimiques
Anesthetics, Inhalation
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
169Informations de copyright
© 2022. The Author(s).
Références
J Opioid Manag. 2021 Sep-Oct;17(5):417-437
pubmed: 34714542
J Int Med Res. 2020 Mar;48(3):300060520904861
pubmed: 32216484
Anesthesiology. 2018 Nov;129(5):932-941
pubmed: 30028726
HPB (Oxford). 2017 Nov;19(11):944-950
pubmed: 28764887
J Transl Med. 2018 Jan 18;16(1):8
pubmed: 29347949
Anesthesiology. 2016 Aug;125(2):399-411
pubmed: 27286478
Cancers (Basel). 2021 Oct 29;13(21):
pubmed: 34771598
J Clin Oncol. 2005 Dec 1;23(34):8664-70
pubmed: 16260700
BMC Anesthesiol. 2019 Jun 12;19(1):102
pubmed: 31185917
Br J Cancer. 2014 Sep 23;111(7):1338-49
pubmed: 25072260
Ann Surg Oncol. 2018 Apr;25(4):845-847
pubmed: 28752469
Cochrane Database Syst Rev. 2017 Apr 04;4:CD011387
pubmed: 28374886
Anesthesiology. 2018 Nov;129(5):921-931
pubmed: 30074934
Pancreas. 2021 May-Jun 01;50(5):648-656
pubmed: 34106573
Am J Surg. 2015 Jun;209(6):969-73
pubmed: 25916614
Dan Med J. 2020 Apr;67(4):
pubmed: 32285797
Anaesthesia. 2010 May;65(5):478-82
pubmed: 20337621
PLoS One. 2020 May 21;15(5):e0233598
pubmed: 32437450
Anesthesiology. 2019 Jan;130(1):31-40
pubmed: 30376457
J Cancer Res Clin Oncol. 2016 Dec;142(12):2489-2496
pubmed: 27605261
Anesthesiology. 2020 Oct 1;133(4):764-773
pubmed: 32930730
Eur J Surg Oncol. 2018 May;44(5):557-558
pubmed: 29530344
BMC Cancer. 2018 Feb 7;18(1):159
pubmed: 29415668
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Br J Anaesth. 2014 Jul;113 Suppl 1:i56-62
pubmed: 25009196
Acta Anaesthesiol Scand. 2019 Oct;63(9):1169-1177
pubmed: 31180151
Dis Colon Rectum. 2021 Aug 1;64(8):946-954
pubmed: 34214054
ANZ J Surg. 2016 Jan-Feb;86(1-2):49-53
pubmed: 26235683
Nat Rev Clin Oncol. 2017 Mar;14(3):155-167
pubmed: 27644321
Value Health. 2010 Mar-Apr;13(2):273-7
pubmed: 19912596
Br J Anaesth. 2020 Aug;125(2):141-148
pubmed: 32475684
Oncol Lett. 2020 Feb;19(2):1187-1194
pubmed: 31966048
Anesthesiology. 2015 Feb;122(2):317-24
pubmed: 25305092
Onco Targets Ther. 2018 Mar 01;11:1141-1148
pubmed: 29535538
J Clin Anesth. 2017 Nov;42:19-25
pubmed: 28797751